The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.

Ginzburg S; Albertsen PC

首页> 外文期刊>Endocrinology and Metabolism Clinics of North America >The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.

【24h】

The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.

机译：前列腺癌雄激素剥夺治疗的时间和范围：权衡临床证据。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Androgen deprivation therapy (ADT) is an effective means of palliating symptoms of prostate cancer but is associated with significant toxicities that increase with treatment duration. Primary ADT in men with localized disease provides no survival advantage. Neoadjuvant ADT, when combined with external beam radiation, improves survival for men with locally advanced disease. Immediate adjuvant androgen deprivation does not seem to benefit most men undergoing radical prostatectomy. No evidence supports combined androgen blockade or monotherapy with nonsteroidal antiandrogens for locally advanced prostate cancer. ADT with orchiectomy or gonadotropin-releasing hormone agonists or antagonists is standard care for men with metastatic prostate cancer.

机译：雄激素剥夺疗法（ADT）是缓解前列腺癌症状的有效手段，但伴随着显着的毒性，这种毒性随着治疗时间的延长而增加。患有局部疾病的男性的原发性ADT没有生存优势。新辅助ADT与外部放射线结合使用时，可以改善患有局部晚期疾病的男性的生存率。立即进行辅助雄激素剥夺似乎并没有使大多数接受前列腺癌根治术的男性受益。没有证据支持联合雄激素阻断或非甾体类抗雄激素单一疗法治疗局部晚期前列腺癌。睾丸切除术或促性腺激素释放激素激动剂或拮抗剂的ADT是转移性前列腺癌男性的标准护理。

著录项

来源
《Endocrinology and Metabolism Clinics of North America》 |2011年第3期|共10页
作者
Ginzburg S; Albertsen PC;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence. [J] . Ginzburg S, Albertsen PC Endocrinology and Metabolism Clinics of North America . 2011,第3期

机译：前列腺癌雄激素剥夺治疗的时间和范围：权衡临床证据。
2. Re: Liselotte MS Boeve, Maarten CCM Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8 [J] . Andres Garcia-Perdomo Herney European urology . 2019,第4期

机译：Re：Liselotte Ms Boeve，Maarten CCM Hulshof，Andre N. Vis等人。与雄激素剥夺治疗相比，对雄激素剥夺治疗的生存对雄激素剥夺治疗与前瞻性随机临床试验中原发性骨转移前列腺癌前列腺患者的同时剥夺治疗的影响：来自血腥审判的数据。 EUR UROL 2019; 75：410-8
3. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial [J] . Boeve Liselotte M. S., Hulshof Maarten C. C. M., Vis Andre N., European urology . 2019,第3期

机译：与雄激素剥夺治疗相比，与雄激素剥夺治疗相结合的雄激素剥夺治疗与前瞻性临床试验中原发性骨转移前列腺癌患者的前列腺患者的生存对雄激素剥夺治疗的生存：来自血腥审判的数据
4. Serum levels of sex hormones before and after androgen deprivation therapy in Japanese prostate cancer patients [C] . A. Komiya, K. Ichimatsu, A. Morii, International Congress of Andrology . 2009

机译：日本前列腺癌患者中雄激素剥夺治疗前后的性激素血清水平
5. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy [D] . TAKEI, Akinori 2019

机译：雄激素剥夺治疗的持续时间和最低20 ng / dL的睾丸激素最低值可预测接受外照射的前列腺癌患者的睾丸激素恢复至超水平
6. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer [O] . Malcolm D. Mason, Wendy R. Parulekar, Matthew R. Sydes, -1

机译：局部晚期前列腺癌联合雄激素剥夺疗法加放疗与单独的雄激素剥夺疗法的小组间随机研究的最终报告
7. LBA18 IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS)IMPACT OF TRANSIENT ANDROGEN DEPRIVATION THERAPY (ADT) WITH LEUPRORELIN LP 11.25 MG ON THE HISTOLOGICAL PROGRESSION OF INDOLENT PROSTATE CANCER (PC)–RESULTS OF A PHASE III TRIAL VERSUS ACTIVE SURVEILLANCE (AS) [O] . Olivier Cussenot, Raphaele Renard Penna, Eva Comperat, 2018

机译：LBA18瞬态抗剥夺治疗（ADT）对Leuprorelin LP 11.25mg对惰性前列腺癌（PC）的组织学进展的影响 - III期试验的第III期试验（AS）对Leuprorelin的影响（ADT）的影响LP 11.25 mg关于惰性前列腺癌（PC）的组织学进展（PC） - III期试验的结果与主动监测（AS）

The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.

摘要

著录项

相似文献

相关主题

期刊订阅